First-line treatment for patients with advanced non-small cell lung carcinoma and high PD-L1 expression: pembrolizumab or pembrolizumab plus chemotherapy
Yixin Zhou, Zuan Lin, Xuanye Zhang, Chen Chen, Hongyun Zhao, Shaodong Hong, Li Zhang
Journal for ImmunoTherapy of Cancer Dec 2019, 7 (1) 120; DOI: 10.1186/s40425-019-0600-6